Leerink Swann Maintains Mylan NV to Outperform with Price Target $45.00

Brokerage firm Leerink Swann Maintains its rating on Mylan NV(NASDAQ:MYL). In a research note issued to the investors, the brokerage major Lowers the price-target to $45.00 per share. The shares have been rated Outperform. The rating by Leerink Swann was issued on Sep 30, 2016.

In a different note, On Sep 23, 2016, Deutsche Bank said it Maintains its rating on Mylan NV. In the research note, the firm Lowers the price-target to $60.00 per share. The shares have been rated ‘Buy’ by the firm. On Aug 15, 2016, Leerink Swann said it Maintains its rating on Mylan NV. In the research note, the firm Raises the price-target to $51.00 per share. The shares have been rated ‘Outperform’ by the firm.

Mylan NV (MYL) shares turned negative on Tuesdays trading session with the shares closing down -0.23 points or -0.60% at a volume of 60,46,464. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $38.35. The peak price level was also seen at $38.35 while the days lowest was $37.62. Finally the shares closed at $37.97. The 52-week high of the shares is $55.505 while the 52-week low is $37.41. According to the latest information available, the market cap of the company is $20,311 M.

Mylan NV(MYL) last announced its earnings results on Aug 9, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $2.56B. Analysts had an estimated revenue of $2.57B. Earnings per share were $1.16. Analysts had estimated an EPS of $1.14.

Several Insider Transactions has been reported to the SEC. On Aug 11, 2016, Heather M Bresch (Chief Executive Officer) sold 100,200 shares at $50.00 per share price.Also, On Jun 6, 2016, Joseph C Md Maroon (director) purchased 1,670 shares at $44.95 per share price.On May 25, 2016, Robert J Cindrich (director) purchased 1,190 shares at $42.47 per share price, according to the Form-4 filing with the securities and exchange commission.

Mylan N.V. formerly Mylan Inc. is a global pharmaceutical company which develops licenses manufactures markets and distributes generic branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Company’s generic pharmaceutical business is conducted primarily in the United States and Canada (collectively North America); Europe the Middle East and Africa (collectively EMEA); and India Australia Japan and New Zealand (collectively Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Company’s API business is conducted through Mylan Laboratories Limited (Mylan India) which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Mylan NV - Is it time to Sell?

Top Brokerage Firms are advising their investors on Mylan NV. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.